Identification of the 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivatives as highly selective PDE4B inhibitors
Graphical abstract
References (11)
- et al.
J. Clin. Invest.
(2002)et al.Cell
(2005) - et al.
Pharmacol. Rev.
(2006)et al.Exp. Opin. Ther. Targets
(2005)Am. J. Respir. Crit. Care Med.
(1998) - et al.
Curr. Med. Chem.
(2006)et al.Drug Discovery Today
(2005)et al.Exp. Opin. Ther. Targets
(2007)et al.J. Med. Chem.
(2008) Br. J. Pharmacol.
(2011)et al.Exp. Opin. Pharm.
(2010)et al.Drug Des. Dev. Ther.
(2010)- et al.
Circ. Res.
(2007)et al.Biochem. J.
(2003)
There are more references available in the full text version of this article.
Cited by (29)
The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure
2021, European Journal of Medicinal ChemistryCitation Excerpt :The carboxylic acid moiety interacted with polar residues in the “S pocket”, and interestingly, the hydroxyl group of tyrosine residue (Tyr274) of UCR2 domain seems to interact with this group, which would contribute to the enhancement of the PDE4B inhibitory activity. It is worth noticing that in PDE4D the tyrosine residue (Tyr274) is replaced by the phenylalanine residue (Phe196), which disfavor the interaction of the pyrimidine derivative 119 with this isoform [179]. Analysis of crystallographic structures of PDE4 shows that “S pocket” is a large region, exposed to the solvent and capable of settle bulky moieties.
Bicyclic 6-6 Systems: Three Heteroatoms 1:2
2021, Comprehensive Heterocyclic Chemistry IVOther Drugs for Asthma and COPD
2021, Encyclopedia of Respiratory Medicine, Second Edition
Copyright © 2014 Elsevier Ltd. All rights reserved.